PATH vs RGEN · P/E 19, rev $1.61B vs P/E 143, $7.43B cap
Uipath Inc (PATH) versus Repligen Corporation (RGEN) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Repligen Corporation (RGEN) is a medical instruments & supplies company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
RGEN does not have a complete income-statement cache yet.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
Not investment advice. Open the PATH and RGEN stock pages for the full models.
Not investment advice.